Ultragenyx Pharmaceutical Inc. (RARE) Net margin 2016–2025
Ultragenyx Pharmaceutical Inc. (RARE) net profit margin by fiscal year — reported net income divided by reported revenue.
-85.4%FY2025 · since FY2016: -184867.7% → -85.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -85.4% | +16.2 pp |
| FY2024 | -101.6% | +38.3 pp |
| FY2023 | -139.9% | +54.8 pp |
| FY2022 | -194.7% | -65.5 pp |
| FY2021 | -129.2% | -60.4 pp |
| FY2020 | -68.8% | +319.5 pp |
| FY2019 | -388.3% | -4.6 pp |
| FY2018 | -383.7% | +11183.6 pp |
| FY2017 | -11567.3% | +173300.3 pp |
| FY2016 | -184867.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice